Oligonucleotide for CNS Europe Summit 2026

We’re looking forward to attending the Oligonucleotide for CNS Europe Summit in Amsterdam this week.

Our Chief Scientific Officer, Andy Billinton, will be presenting on Thursday at 3:00pm (CET), sharing perspectives on advancing oligonucleotide approaches to address new targets for CNS disorders.

It’s an exciting moment for the field, with growing momentum around innovative modalities and their potential to address complex neurological conditions.

If you’re attending, we’d love to connect.

hashtag#Oligonucleotides hashtag#CNS hashtag#Biotech hashtag#DrugDiscovery hashtag#Neuroscience hashtag#LifeSciences hashtag#Innovation

Our programmes

Huntington's Disease

ALS and Alzheimer's

Our news

February 2026

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board

Read more

October 2025

Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment

Read more

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

Read more

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

Read more